Can backward-looking volatility ever be profitable?

clock • 2 min read

Just over a month ago, volatility, as measured by the VIX index was around 26%, the highest reading since the Chinese slowdown scare of last August. The FTSE 100 was plunging, reaching its nadir of 5,500 in the morning of 11 February.

Since then, the EU referendum has kicked off, adding to uncertainty, but the FTSE 100 is now 12% higher at the time of writing. The first catalyst for this has been the recovery in the oil price and this has removed much of the immediate focus on the sector and reduced global market tension. What has become very clear is there was a significant degree of market manipulation taking place. We have heard reports over 80% of the transactional activity influencing the oil price was paper-based, rather than driven by actual oil users.   The wider equity markets are increasingly manipulat...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot